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The EU Clinical Trials Regulation: Key Priorities, Purposes and Aims and the Implications for 
Public Health 
Mark L Flear* 
I Introduction 
The replacement of the European Union (EU) Clinical Trials Directive[1] (CTD) by the new Clinical 
Trials Regulation[2] (CTR), which entered into force on 16 June 2014 but will not apply before 28 
May 2016 (Article 99 CTR),1 provides an opportunity to review the legal and political context within 
which this important aspect of research law and policy sits and reflect on the implications for public 
health. This article therefore supplements the two more detailed considerations of specific aspects of 
the CTR in this issue.[3] My aim is to relate the context to the key purposes and aims of EU law and 
policy on clinical trials2 in order to explain and clarify its orientation. On that basis I build on my 
previous work[4-5] to argue that the CTR and the changes it introduces to the law on clinical trials are 
part of the EU’s continued focus on market optimisation. It is this focus that orients and directs the 
pharmaceutical development pipeline as a whole, but that undermines the achievement of key public 
health objectives. 
Specifically, the CTR seeks to improve safety data production as the basis for licensing new products, 
supporting corporate profitability and optimising the economy. However, this overall focus feeds into 
the skewing of resources and attention towards pharmaceutical (often treatment-based) responses to 
public health problems (a process often referred to as ‘pharmaceuticalisation’), but with detrimental 
consequences for public health.[6-7] Consequences include the neglect of research and development in 
and the unavailability of pharmaceuticals that could tackle the biggest causes of mortality and 
morbidity globally[8] (especially in the global South,3 a situation exacerbated by global patents4).[4-5] 
In an era when communicable diseases tend to garner more resources and attention as threats to public 
health than non-communicable diseases, a focus on pharmaceutical-fixes might aggravate the effects 
of the social conditions that mean the latter loses out.5 A focus on pharmaceuticals also means that 
wider non-pharmaceutical (usually preventative) public health interventions that would tackle both 
communicable and non-communicable diseases receive less resources and attention, despite their 
being cheaper and more effective at producing better overall improvements in public health.6 The 
public health implications of the CTR are, therefore, an important ethical matter that might be 
overlooked without the attention to the wider legal and political context that this article provides. 
                                                          
* My thanks to Muireann Quigley for comments on earlier drafts. This article was written during a sabbatical 
during the 2015-16 academic year – my thanks to School of Law, Queen’s University Belfast for this time to 
focus on research. 
1 The CTD continues to apply in a transitional period, see Article 98 CTR. 
2 The law discussed here applies not only to the EU, but also the wider European Economic Area (or EEA). The 
EEA comprises the 28 Member States of the EU and three members of the European Free Trade Association 
(EFTA), Iceland, Liechtenstein and Norway. Switzerland, the fourth EFTA Member State, maintains an 
association agreement with the EEA. For the sake of simplicity the article refers to, for example, ‘EU law’. 
3 The so-called 10/90 research gap in which only 10 per cent of global health research is spent on problems that 
affect 90 per cent of the global population, especially poverty-related diseases. The gap has narrowed slightly 
but remains a key concern. 
4 Provided under the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs). The public 
health friendly flexibilities under this framework are seldom used and are being undercut by so-called TRIPs-
plus agreements. Marrakesh Agreement Establishing the World Trade Organisation (WTO), opened for 
signature 15 April 1994, 1867 UNTS 3, annex 1C TRIPs (entered into force 1 January 1995). Under TRIPs it is 
for WTO Member States (which includes EU Member States) to determine what deserves to be patented, and as 
such countries in the industrialised global North, ie, where the biggest producers of pharmaceuticals have their 
homes, are effectively able to export their patent protections.  
5 As I argue in references [4-5] these conditions are apparent at the EU level, where (as elsewhere) risk and 
security frame the regulation of and interventions in public health.  
6 The argument advanced here is that the CTR represents a continuation of current focus and orientation, and for 
that reason it continues to undermine the achievement of public health objectives. 
The starting point for my account, in the next section, is to begin by noting the joint scientific and 
ethics-based rationale that is foregrounded in the CTR and then explaining how it is used to justify the 
adoption of an EU regulation. After which I outline the main changes introduced by the CTR. In the 
third section I deepen the discussion in order to underline the deeper (and less prominent) market-
oriented purposes and aims of the CTR. In order to do so I explain how the CTR relates to the EU’s 
programmatic priorities of creating a dynamic and innovative market-based economy and economic 
optimisation. I explain how those priorities are reflected in the alignment of the CTR to market 
authorisation as part of the pharmaceutical development pipeline. Finally, I discuss the way in which 
the legal basis for the CTR is used to set its market-oriented purposes and aims so as to meet those 
broader priorities.  
II Introducing the EU Clinical Trials Regulation 
A Clinical Trials and EU Law 
Clinical trials are a type of clinical research and therefore an important part of the pharmaceutical 
development pipeline7 or ‘cycle of innovation’. This begins with an idea that drives basic research, 
leading (where successful) to non-clinical, pre-clinical, and clinical research, and from there (where 
successful) to improvements and licensing for sale and use for treatment within the market and 
subsequent surveillance (or pharmacovigilence).[9] Clinical research can involve so-called 
‘translational’ research or the ‘from bench-to-bedside’ approach that aims to turn laboratory 
experiments (here in pharmaceuticals) through clinical research into marketable products. In all there 
are four phases of clinical trials. Phase I trials use between 20–80 healthy volunteers in order to 
determine the tolerable dose range of a new drug. In order to evaluate the efficacy and safety of the 
drug phase II trials involve between 100–300. Phase III trials tend to be multi-centred and might 
involve up to 10,000 people located in between 10–20 countries. This phase generates more safety 
and efficacy data. Both phase I and phase II trials tend to involve subjects who have the disease or 
condition to be treated. Phase IV trials are used to generate more safety and efficacy data, but post-
marketing of the drug. This phase can involve millions of people. 
In 2001 clinical trials for pharmaceuticals became the subject of EU law through the adoption of the 
CTD. This legal instrument required Member States to set standards for the planning, performance, 
reporting, and archiving of research for new pharmaceuticals or ‘medicinal products’ (see the CTD’s 
full name[1]). Member States were also required to establish systems of monitoring and inspection in 
relation to good clinical practice (GCP), many of which are further concretised in subsequent 
legislation.[10] In short, the CTD provided the standards that apply to the production of data that is 
used to authorise the marketing of ‘medicinal products’ within the EU’s internal market. The internal 
market is defined in Article 26(2) TFEU as, ‘an area without internal frontiers in which the free 
movement of goods, persons, services and capital is ensured’ (the establishment of the internal market 
is required by Article 3(3) TEU). Market authorisation is subject to further EU legislation (which I 
outline below). The legal foundation for the adoption of any EU legislation is in the (EU) Treaties, 
which comprise a skeletal Treaty on European Union (TEU) that is fleshed out in the Treaty on the 
Functioning of the European Union (TFEU). EU competence in respect of the internal market is 
shared with the Member States (under Article 4(2)(a) TFEU). What is now Article 114 TFEU 
provides the basis for the adoption of harmonising legislation for the establishment and functioning of 
the internal market,8 which therefore includes that on clinical trials and market authorisation (I return 
to this common legal basis and discuss its significance in relation to the CTR below). 
 
A core focus of the CTD was on ensuring compliance with the Helsinki Declaration’s[11] (Helsinki) 
ethics-based protections for human research subjects, including their informed consent and research 
ethics committees that determine the permissibility of involving human subjects in the first place. 
                                                          
7 Clinical trials refer to a broader category of trials of pharmaceuticals and medical techniques and practices in a 
clinical setting. 
8 Where the EU has competence any legislation adopted must also be justified by the principles of subsidiarity 
and proportionate under Article 5(3) TEU and Article 5(4) TEU respectively. 
Within the Helsinki Declaration the ethical permissibility of involving research subjects is tied to the 
scientific enterprise of creating, refining and advancing scientific knowledge,[12] in order to ‘improve 
preventive, diagnostic and therapeutic interventions (methods, procedures and treatments)’ (para 9) 
(emphasis added). To this end the interests of the subjects must not be subordinated to the interests of 
society. A calculation of risk and benefit is deployed to ensure the research subject is not worse off for 
being involved than she would have been otherwise.  
 
B Rationale for Adopting a ‘Regulation’ in EU Law 
Experience under the CTD gave rise to concerns that differences in its application in the EU’s (now) 
28 Member States (up from 15 in 2001, the year of the CTD’s adoption) would undermine scientific 
research. These differences were exacerbated by the ‘cumbersome procedures for multi-centre clinical 
trials in different Member States’ leading to an ‘impact on academic as well as non-academic 
research’.[13] In particular, ‘Scientific development...suggests that future clinical trials will target more 
specific patient populations, such as subgroups identified through genomic information. In order to 
include a sufficient number of patients for such clinical trials it may be necessary to involve many, or 
all, Member States’ (Recital 4 CTR).[14] Consequently, it became necessary to reconsider the legal 
form or instrument in respect of clinical trials (consistent with the legal basis for internal market 
legislation under Article 114 TFEU). 
As summarised in the CTR, the adoption of a regulation ‘would present advantages for sponsors and 
investigators, for example in the context of clinical trials taking place in more than one Member State, 
since they will be able to rely on its provisions directly [before national courts]’ (emphasis added) 
(Recital 5 CTR).9 By contrast the CTD (as a directive) could only be relied upon directly in very 
specific circumstances;10 which meant that in most cases domestic implementing legislation was 
applicable. In the case of the United Kingdom, for example, the CTD was adopted into domestic law 
by its transposition through the Medicines for Human Use (Clinical Trials) Regulations 2004.[15] In 
short, the adoption of an EU regulation (the CTR) more uniformly harmonises (that is, standardises) 
and enhances the efficacy and uniformity of EU law across the EU (and in third countries – as noted 
above clinical trials carried out in them that feed into the EU’s clinical trials and market authorisation 
processes must comply with the requirements of EU law). 
 
C Overview of Changes under the Clinical Trials Regulation 
 
The CTR has a strong scientific rationale (as we have just seen) and it is entwined with an ethical 
rationale through the continued focus on the protection of human research subjects (embedded 
throughout and including: Recitals 15, 17, 27, 44, 76 and 80, Article 3 and Chapter V (on protection 
of subjects and informed consent) CTR). On the basis of this joint rationale the CTR introduces a 
number of key changes to the law on clinical trials that applies in EU Member States (more specific 
changes will also be introduced in respect of GCP11). The first change under the CTR is the 
                                                          
9 Article 288 TFEU defines directives and regulations and specifies that they can be adopted for the ‘exercise of 
the Union’s competences’. A directive is ‘binding, as to the result to be achieved, upon each Member State to 
which it is addressed, but shall leave to the national authorities the choice of form and methods’. By contrast a 
regulation has ‘general application. It shall be binding in its entirety and directly applicable in all Member 
States’. 
10 The Court of Justice of the European Union (CJEU) has found that provided they are sufficiently clear, 
precise and unconditional the provisions of directives can be relied upon before Member State courts as against 
the Member State only (that is, not individuals), but only where their deadline for implementation has passed 
and the Member State has not properly implemented them (Case 71/74 Van Duyn v Home Office [1974] ECR 
1337; Case 148/78 Pubblico Ministero v Tullio Ratti [1979] ECR 1629). By contrast the CJEU has found that 
regulations are capable of being relied upon before Member State courts as against the Member State and 
individuals, as appropriate, from the date they enter into force and become applicable (as specified in the 
specific instrument) (Case 39/72 Commission v Italy [1973] ECR 101). 
11 For the state of play at time of publication, see: Implementation measures by the Commission in the context 
of Regulation (EU) No 536/2014 – overview and state of play. 
http://ec.europa.eu/health/files/clinicaltrials/overview_clinical_trials.pdf (accessed 9 December 2015). 
introduction by the European Medicines Agency (EMA) of an EU portal that serves as a single entry 
point for the submission of an application for the authorisation of clinical trials to the reporting 
Member State (Article 5, Article 16 and Article 80 CTR12) and an EU database for the storage of the 
application and related data (Article 81 CTR). There is a single set of application documents and a 
two-part application process. Part I centres on the necessity of the trial and the balance of risk and 
benefit of participation by human research subjects. Part I is led by the reporting Member State and 
jointly assessed by all Member States that have trial sites (Article 6 CTR referring to Chapter V). Part 
II centres on ensuring compliance with the requirements for informed consent and recruitment of 
research subjects, rewarding or compensating research subjects, data protection, suitability of those 
involved in conducting the trial and trial sites, and damage compensation. Compliance with these 
requirements is assessed separately by each of the Member States where there is a trial site (Article 7 
CTR). The assessment of the clinical trial authorisation application and the work of Research Ethics 
Committees is subject to strict deadlines.13 Legal certainty for small and medium sized enterprises 
(so-called SMEs) and academics, the main sponsors of clinical trials, is improved through the 
extension of the tacit agreement principle to the entire authorisation process ‘in order to ensure that 
timelines are adhered to’ (Recital 8 CTR).14  
Reporting of clinical trial results is also simplified through their submission to the EU portal for 
storage on the EU database. Transparency is improved through the public availability of all 
information (in principle15) on the clinical trials application and reporting of results submitted via the 
EU portal and placed in the database (especially under Article 37(4) CTR).16 Increased public 
availability is important for medical professionals, researchers and patients who seek to access, for 
example, the data on the safety and efficacy of licensed pharmaceuticals or simply to find out what 
has and has not been trialled and the results. Supervision and enforcement of EU law on clinical trials 
in Member States and third countries has also been reinforced (Chapter XIII CTR).  
Finally, where applications for the authorisation of clinical trials make reference to data derived from 
trials carried out in third countries, those trials must adhere to standards that are ‘equivalent’ to those 
found in the CTR (Article 25(5) CTR). Further, the trials referred to must have been registered in a 
public register which is a primary or partner registry of, or a data provider to, the World Health 
Organisation’s International Clinical Trials Registry Platform (or WHO ICTRP) (Article 25(6)(1) 
CTR). These changes build on the requirements in the Community code relating to medicinal products 
for human use (Community code).[16] The requirements apply to clinical trials data produced in 
compliance with the CTR (formerly the CTD) as the evidence base for market authorisation. The 
Community code provides that in relation to third countries, clinical trials conducted in them that 
                                                          
12 In the first instance the trial sponsor shall propose the reporting Member State. In the event that this proposal 
is declined more detailed rules determine which Member State shall report. 
13 For example, under Article 5(3) CTR the reporting Member State must validate the application ‘Within 10 
days from the submission of the application dossier’, and under Article 6(4) CTR that Member State must 
‘submit, through the EU portal, the final Part I of the assessment report, including its conclusion, to the sponsor 
and to the other Member States concerned within 45 days from the validation date’. 
14 An example of tacit agreement that follows on from Article 5(3) CTR (ibid) is that found in Article 5(4) CTR: 
‘Where the reporting Member State has not notified the sponsor within the period referred to in…[Article 5(3)], 
the clinical trial applied for shall be deemed to fall within the scope of this Regulation and the application 
dossier shall be considered complete’ (emphasis added). 
15 Confidentiality of the information can be justified on the grounds specified in Article 81(4) CTR, including 
the protection of commercially confidential information and the protection of personal data. 
16 In particular, Article 37(4)(1)-(2) CTR provides that regardless of the outcome of a clinical trial the sponsor 
‘shall submit to the EU database a summary of the results of the clinical trial’ (as detailed in Annex IV) and a 
layperson summary (as detailed in Annex V) within one year from the end of a clinical trial in all Member 
States concerned. Article 37(4)(4) CTR provides where the ‘clinical trial was intended to be used for obtaining a 
marketing authorisation for the investigational medicinal product, the applicant for marketing authorisation shall 
submit to the EU database the clinical study report within 30 days after the day the marketing authorisation has 
been granted, the procedure for granting the marketing authorisation has been completed, or the applicant for 
marketing authorisation has withdrawn the application’. The clinical study report is submitted in addition to the 
summary of results. 
provide data used in an application for market authorisation are subject to standards that are 
‘equivalent’ to (rather than the same as) those applicable in the Member States under the CTR 
(formerly the CTD).17 
Further discussion of these specific changes, in particular on the satisfactoriness of ethical 
protections,[17] lies outside the scope of this article. Instead, my aim is to point out how the CTR has 
implications for public health that arise from its specific priorities and aims and the wider purposes it 
reflects and serves. But the changes are far from unimportant to that discussion. In the following I link 
the significance of the CTR’s legal form and the changes it introduces to the achievement of broader 
programmatic priorities. After which I explain how these are reflected in the CTR’s place and role in 
the pharmaceutical development pipeline and its market-oriented purposes and aims. In light of this 
legal and political context the new regulation shall gain particular significance in that it becomes 
clearer how it facilitates the market availability of pharmaceuticals and supports the achievement of 
the EU’s broader market-oriented priorities, while undermining public health objectives. 
III Situating EU Law and Policy on Clinical Trials: Deeper Market-Oriented Priorities, 
Purposes and Aims 
A Programmatic Priorities  
Concerns over differences in the application of the law on clinical trials become acute when they not 
only jeopardise the efficacy and uniformity of EU law, but also the achievement of specific market-
oriented purposes and aims, and with them broader programmatic priorities; ie the market availability 
of new ‘medicinal products’ and all that hinges on them. It is this concern for markets that ultimately 
drives and justifies the adoption of the CTR and its modifications of EU law on clinical trials, but not 
without detrimental consequences for public health objectives. The EU’s programmatic priorities 
provide the broad steer and direction for EU law and policy across all domains, including EU law and 
policy on clinical trials and the wider pharmaceutical development pipeline. In the 2000 European 
Council Lisbon Strategy[18] research was presented as ‘the driver for the production and exploitation 
of knowledge [making it] above all a linchpin in the implementation of the Lisbon strategy to make 
Europe the most dynamic and competitive, knowledge-based economy in the world, capable of 
sustaining economic growth, employment and social cohesion’[19] (emphasis added). The Lisbon 
Strategy is part of the so-called ‘knowledge triangle’ of research, education and innovation[20] that 
constitutes the European Research Area. The latter aims to ‘reinvigorate research in Europe’[21] 
through EU funding of research and development. The focus is on enabling discourse between 
researchers in different Member States in order to foster the economic competitiveness of European 
industry, and integration.[22] Subsequent iterations of the Lisbon Strategy have gradually narrowed the 
focus to generating economic growth and jobs,[23] especially after the recent European financial crisis, 
which led in 2010 to the Commission’s Europe 2020 strategy that sought to invigorate economic 
growth.[24-27] 
A key Europe 2020 flagship initiative is the innovation union, which ‘aims to maximise the EU's 
capacity for innovation and research and channel it towards societal challenges. The European 
Commission's aim is to make Europe a world-leader in developing innovative ways to promote active 
and healthy ageing – a challenge common to all European countries’[28] (emphasis added, except for 
‘active and healthy ageing’). Noteworthy here is how innovation is linked to research, and this is then 
directed at tackling societal challenges. Societal optimisation including in relation to health is aimed 
at the economy – it is to ‘boost and improve the competitiveness of the markets for innovative 
products and services that respond to the ageing challenge both at EU and global level, thus creating 
new opportunities for businesses’[28] (emphasis added). Funding to support the programmatic 
                                                          
17 Article 8(3)(ib) provides that these particulars shall include a ‘statement to the effect that clinical trials carried 
out outside the European Union meet the ethical requirements of Directive 2001/20/EC’ (emphasis added). 
Annex I, point 8 clarifies that these clinical trials are must be carried out ‘on the basis of principles, which are 
equivalent to the provisions of Directive 2001/20/EC. They shall be carried out in accordance with the ethical 
principles that are reflected, for example, in the Declaration of Helsinki’ (emphasis added). 
priorities in the seventh (and final) Framework Programme, FP7,[29] was directed at research[30] – 
including in biomedicine18 – in order to drive future growth instead of as a means of increasing 
knowledge and understanding per se. The same orientation is found in (the current) Horizon 2020.[31] 
Within Horizon 2020 (and FP7 before it) funding is limited by the need to ensure ‘added value’. 
Translational research, ie bringing innovations into the EU’s marketplace or internal market is an area 
where the EU can add value, including in relation to clinical trials. Indeed, since ‘the translation of 
basic discoveries into clinical applications is one of the main objectives of this theme [in FP7 – and 
now Horizon 2020], clinical research, including clinical trials, is expected to be a major tool used in 
the funded projects’[32] (emphasis added). 
Even when health is apparently the focus, such as in 2007’s Together for Health: A Strategic 
Approach for the EU 2008-2013[33] (Together for Health), it is again linked to economic priorities. For 
instance, it is noted ‘This Strategy reinforces the importance of health in policies such as the Lisbon 
Strategy for Growth and Jobs, emphasising the links between health and economic prosperity’ (p 2) 
(emphasis added). In other words, Together for Health ‘supports the overall Europe 2020 strategy’[34] 
for economic growth. Funding to support Together for Health under the EU’s health programme, now 
in its third iteration (for 2014-2020),[35] is directed at meeting the priorities of Europe 2020. For 
instance, ‘[i]n line with the objectives of the Europe 2020 Strategy, the Programme should focus on a 
set of well-defined objectives and actions with clear, proven Union added value, and concentrate 
support on a smaller number of activities in priority areas’[35] (Recital 5) (emphasis added) including 
health. As with Horizon 2020 funding, this is seen in the focus is on translational research such as 
clinical trials ‘by promoting, where relevant, the uptake of innovative breakthroughs resulting from 
research in the health sector’[35] (Recital 21). This vision is clearly beneficial for the ‘big pharma’[36] 
dominated pharmaceuticals industry, which enjoyed a boom period in the 1990s but is now struggling 
to deliver sufficient numbers of new ‘blockbuster drugs’. Supporting clinical trials for translation into 
marketable pharmaceuticals seeks to enhance the EU’s internal market, develop an innovative and 
competitive industry,[37] and in turn support the EU’s project of European integration. 
B Developing Pharmaceuticals for the Market 
 
The way in which clinical trials are made integral to the development and ultimately the marketing of 
pharmaceuticals in order to meet the EU’s programmatic priorities is especially apparent in the 
alignment of the objective of clinical trials with the criteria for market authorisation, such as under the 
so-called centralised procedure.19 There are several other types of procedure for market authorisation 
within the EU’s internal market[38] and (as summarised above) each of them requires compliance with 
the Community code and it is this that forms the link with clinical trials. That is because the 
Community code mentions clinical trials data as the basis for the market authorisation of 
pharmaceutical treatments on the grounds of their quality, safety and efficacy (embedded throughout 
the Community code). 
 
The very definition of clinical trials in the CTR (and the CTD before it) highlights their alignment to 
the requirements for market authorisation under the Community code. Under the CTR clinical trials 
are clarified as being a type of clinical study20 that is an investigation: 
 
‘in relation to humans intended: (a) to discover or verify the clinical, pharmacological or other 
pharmacodynamic effects of one or more medicinal products; (b) to identify any adverse 
                                                          
18 Research into biomedical applications is highlighted in the FP7 objectives, in such references as ‘the 
development and validation of new therapies[…]diagnostic tools and medical technologies’. See [30]. 
19 Of course, a clinical trial might not be intended to generate data for market authorisation, for instance where 
the objective is simply to widen the knowledge base on treatments.  
20 Article 2(2)(2) CTR provides ‘clinical study’ ‘means any investigation in relation to humans intended: (a) to 
discover or verify the clinical, pharmacological or other pharmacodynamic effects of one or more medicinal 
products; (b) to identify any adverse reactions to one or more medicinal products; or (c) to study the absorption, 
distribution, metabolism and excretion of one or more medicinal products; with the objective of ascertaining the 
safety and/or efficacy of those medicinal products’. 
reactions to one or more medicinal products; or (c) to study the absorption, distribution, 
metabolism and excretion of one or more medicinal products; with the objective of 
ascertaining the safety and/or efficacy of those medicinal products’ (Article 2(2)(1) CTR).21 
(Emphasis added) 
 
The similar focus on the quality, safety and efficacy of pharmaceuticals (ie ‘medicinal products’) in 
the CTR and Community code rather than a wider test of ‘comparative therapeutic efficacy’ and 
genuine need (a point I return to later) is unsurprising. Indeed, legal consistency across these 
instruments is important in order to ensure their joint efficacy and uniform application as part of the 
pharmaceutical development pipeline that facilitates the marketing of new pharmaceuticals (approval 
figures are important for communicating success and performance).[39-40] 
 
C Renewed Significance of the Common Legal Basis of EU Law on Clinical Trials and Market 
Authorisation 
 
The similar focus in EU clinical trials and market authorisation legislation and its orientation towards 
the market is facilitated by the aforementioned common legal basis in Article 114 TFEU. Further 
attention to this basis underscores the purposes and aims of EU law in these connected areas; and the 
way in which the basis is used in respect of the CTR in order to meet the EU’s broader programmatic 
priorities. Article 114(3) TFEU requires the Commission to take ‘as a base a high level of protection’ 
including inter alia health. This is a more specific instantiation of Article 9 TFEU, a provision of 
general application which provides ‘the Union shall take into account requirements linked to … a 
high level of … protection of human health’ (emphasis added) in the definition and implementation of 
its policies and activities, which of course includes clinical trials and market authorisation. The EU 
also has competence to support Member State actions in respect of the protection and improvement of 
health (Article 6(a) TFEU), but while Article 168 TFEU provides the legal basis for the adoption of 
supporting legislation it excludes any harmonisation (Article 168(5) TFEU). 
 
The importance of the internal market and the protection of human health can be seen in slightly 
different but nevertheless related ways in both the Community code and CTR. Under the Community 
code the ‘essential aim of any rules governing the production, distribution and use of medicinal 
products must be to safeguard public health’[16] (Recital 2) (emphasis added). But this aim is 
immediately followed by the qualification that it ‘must be attained by means which will not hinder the 
development of the pharmaceutical industry or trade in medicinal products within the Community 
[now Union]’[16] (Recital 3) (emphasis added). The principle aim here is the establishment and 
functioning of the internal market – and the protection of human health is constructed in a very 
specific way such that it is effectively subordinated to market interests. Further, reflecting the narrow 
criteria for market authorisation and the purpose of clinical trials the public health implications of 
pharmaceuticals are confined to their safety. 
 
While the CTD, like the other pieces of legislation discussed here, was based on the EU’s competence 
in relation to the internal market, similar statements of purposes and aims are not present. However, 
under the CTR the link between clinical trials and pharmaceutical product marketing is specified and 
tightened through its foundation on the dual legal basis of Articles 114 TFEU and Article 168(4)(c) 
TFEU. These provisions provide objectives that are ‘pursued simultaneously’ and ‘one is not 
secondary to another’ (Recital 82 CTR). As regards Article 114 TFEU, the CTR: 
 
‘harmonises the rules for the conduct of clinical trials in the Union, therefore ensuring the 
functioning of the internal market in view of the conduct of a clinical trial in several Member 
States, the acceptability throughout the Union of data generated in a clinical trial and 
submitted in the application for the authorisation of another clinical trial or of the placing on 
the market of a medicinal product, and the free movement of medicinal products used in the 
context of a clinical trial’ (Recital 82 CTR). (Emphasis added) 
                                                          
21This definition is very similar to that under Article 2(a) CTD. 
In a derogation from the limits on EU competence for the protection and improvement of health, 
Article 168(4)(c) TFEU builds on the shared competence in respect of the common safety concerns in 
respect of public health matters (Article 4(2)(k) TFEU). With this provision as a legal basis the CTR 
is used to set: 
‘high standards of quality and safety for medicinal products by ensuring that data generated 
in clinical trials are reliable and robust, thus ensuring that treatments and medicines which 
are intended to be an improvement of a treatment of patients build on reliable and robust 
data. Moreover, this Regulation sets high standards of quality and safety of medicinal 
products used in the context of a clinical trial, thus ensuring the safety of subjects in a clinical 
trial’ (Recital 82 CTR). (Emphasis added) 
This statement might imply that a key aim of the CTR is to produce clinical trials data that will 
demonstrate a new pharmaceutical is an improvement over what is already available. However, this is 
not necessarily the case. As the EMA explains in its ‘soft law’ guidance ‘it is not necessary for the 
benefit-risk profile of an experimental medicine to [be] at least as favourable as the benefit-risk 
profile of any or all established medicines in order to receive marketing authorisation’[41] (emphasis 
added). For example, producing a new pharmaceutical that has fewer side-effects can be useful, as can 
having multiple equally effective medicines available as a way of tackling resistance to medication. 
Consistent with the criteria for market authorisation (quality, safety and efficacy) clinical trials need 
only at the bare minimum ensure that pharmaceuticals are as good as or at least no worse than existing 
products. In other words, in order to be licensed the new pharmaceutical need not be an improvement 
over what is already available and clinical trials need only demonstrate that is the case.[4-5] 
 
In sum, the deeper and overall purpose and aim of the CTR is to get pharmaceuticals through the 
development pipeline and onto the market as quickly as possible. But the CTD inhibited the 
production of data on product safety (particularly where multi-site trials are required) and undermined 
the market availability of new pharmaceuticals. This (it is supposed) in turn impacted negatively on 
sales, the return on research and development costs, and the corporate bottom line. Specific decisions 
about the CTR – the selection of the legal form of a regulation, how to utilise the dual legal basis and 
the changes introduced – are made and justified by the need to speed up the pharmaceutical 
development pipeline and the achievement of wider market-oriented programmatic priorities. Indeed, 
as stated in the CTR: ‘The timelines for assessing an application dossier for clinical trials should be 
sufficient to assess the file while, at the same time, ensuring quick access to new, innovative 
treatments and ensuring that the Union remains an attractive place for conducting clinical trials’ 
(Recital 8 CTR) (emphasis added). 
IV Conclusion 
While product safety is essential, the focus on it in EU clinical trials and market authorisation law and 
policy is not in itself sufficient to bring about the vision of the scientific enterprise in this area, ie 
creating improvements in public health that are to the benefit of society at large. Instead, the CTR 
ensures that knowledge creation through clinical trials fits better with scientific developments and 
wider law and policy on the pharmaceutical development pipeline. As part of the pipeline clinical 
trials are oriented towards producing a version of economic optimisation that supports private 
commercial profitability through the marketing of ‘more of the same, if not worse’. To some extent 
this might be understood as a consequence of the relative strength of the EU’s competence in relation 
to the internal market as compared to public health. However, the direction and orientation of EU 
clinical trials law and policy reflects broader programmatic priorities. It is in light of these priorities 
that the focus on safety matters becomes more easily viewed as a specific decision about how to make 
use of EU competence in respect of pharmaceutical development and marketing within the internal 
market. 
Nevertheless, since the EU is under an obligation to take into account the protection of human health 
at a high level in all areas of its activities, it could yet adopt internal market harmonisation legislation 
that ensures better protection of human health. In other words, it remains possible for the EU (through 
its legislature) to make a different decision: one that better realises the achievement of public health 
objectives. Crucially the EU could decide to recast the criteria for market authorisation, and align 
clinical trials to it, so that there is a focus throughout the development pipeline on the safety and 
comparative efficacy of new pharmaceuticals as well as a genuine need for them.22 Such a change 
would be more in the spirit of the scientific enterprise and go some way to rebalancing the 
prioritisation of interventions and public health problems, and better achieving overall public health 
outcomes. This change would also mean the EU better fulfils its responsibilities for the internal 
market and public health. But this decision remains a distant prospect while the EU’s programmatic 
priorities are focused on the internal market and a very particular version of economic optimisation 
rather than meeting important and wider public health needs and objectives. 
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